Abstract
Background: Over the last twenty years, the efforts of the scientific community devoted to the comprehension and treatment of ovarian cancer have remained poorly remunerative, with the case-fatality ratio of this disease remaining disappointedly high. Limited knowledge of the basic principles regulating ovarian carcinogenesis and factors impacting the course of disease may significantly impair our ability to intervene in early stages and lessen our expectations in terms of treatment outcomes. In the present study, we sought to assess whether metabolic factors and anthropometric indicators, i.e., pre-treatment fasting glucose and body mass index, are associated with renown cancer related prognostic factors such as tumour stage and grade at diagnosis. Materials and Methods: Study participants were 147 women diagnosed with epithelial ovarian cancer and treated with platinum based regimens and/or surgery at the Regina Elena National Cancer Institute of Rome, Italy. Glucose levels were assessed at the institutional laboratories on venous blood collected in overnight fasting conditions and prior to any therapeutic procedure. Stage was coded according to the FIGO staging system based on the results of the diagnostic workup, while tumour grade was locally assessed by an expert pathologist. Participants' characteristics were descriptively analyzed for the overall study population and in a subgroup of 70 patients for whom data on body mass index (BMI) were available. FIGO stage and grade were compared by categories of pre-treatment fasting glucose defined upon the median value, i.e., 89 mg/dl. The association of interest was tested in regression models including BMI. Results: For the overall study population, patients in the lowest category of fasting glucose were significantly more likely to exhibit a FIGO stage III-IV at diagnosis compared with their counterpart in the highest glucose category (81.3 vs 66.7%, p: 0.021). Subgroup analysis in 70 patients with BMI data confirmed this association (81.5 vs 55.8, p: 0.049), which remained significant when tested in regression models including BMI (OR: 0.28 95% CI 0.086-0.89, p: 0.031). No relevant evidence emerged when testing the association between fasting glucose and tumour grade. Conclusions: In patients diagnosed with epithelial ovarian cancer, pre-treatment glucose levels appear to be inversely associated with FIGO stage. Further studies are warranted to eventually confirm and correctly interpret the implications of this novel finding.
| Original language | English |
|---|---|
| Pages (from-to) | 516-522 |
| Number of pages | 7 |
| Journal | Journal of Cancer |
| Volume | 7 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2016 |
Fingerprint
Keywords
- Body mass index
- Epithelial ovarian cancer
- Fasting glucose
- FIGO stage
- Tumour grade
ASJC Scopus subject areas
- Oncology
Cite this
Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients. / Vici, Patrizia; Pizzuti, Laura; Di Lauro, Luigi; Conti, Laura; Mandoj, Chiara; Antenucci, Anna; Digiesi, G.; Sergi, Domenico; Amodio, A.; Marchetti, Paolo; Sperati, F.; Valle, Mario; Garofalo, Alfredo; Vizza, Enrico; Corrado, Giacomo; Vincenzoni, C.; Tomao, Federica; Kayal, Ramy; Marsella, Annalise; Carosi, Mariantonia; Antoniani, B.; Giordano, Antonio; Maugeri-Saccà, Marcello; Barba, Maddalena.
In: Journal of Cancer, Vol. 7, No. 5, 2016, p. 516-522.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients
AU - Vici, Patrizia
AU - Pizzuti, Laura
AU - Di Lauro, Luigi
AU - Conti, Laura
AU - Mandoj, Chiara
AU - Antenucci, Anna
AU - Digiesi, G.
AU - Sergi, Domenico
AU - Amodio, A.
AU - Marchetti, Paolo
AU - Sperati, F.
AU - Valle, Mario
AU - Garofalo, Alfredo
AU - Vizza, Enrico
AU - Corrado, Giacomo
AU - Vincenzoni, C.
AU - Tomao, Federica
AU - Kayal, Ramy
AU - Marsella, Annalise
AU - Carosi, Mariantonia
AU - Antoniani, B.
AU - Giordano, Antonio
AU - Maugeri-Saccà, Marcello
AU - Barba, Maddalena
PY - 2016
Y1 - 2016
N2 - Background: Over the last twenty years, the efforts of the scientific community devoted to the comprehension and treatment of ovarian cancer have remained poorly remunerative, with the case-fatality ratio of this disease remaining disappointedly high. Limited knowledge of the basic principles regulating ovarian carcinogenesis and factors impacting the course of disease may significantly impair our ability to intervene in early stages and lessen our expectations in terms of treatment outcomes. In the present study, we sought to assess whether metabolic factors and anthropometric indicators, i.e., pre-treatment fasting glucose and body mass index, are associated with renown cancer related prognostic factors such as tumour stage and grade at diagnosis. Materials and Methods: Study participants were 147 women diagnosed with epithelial ovarian cancer and treated with platinum based regimens and/or surgery at the Regina Elena National Cancer Institute of Rome, Italy. Glucose levels were assessed at the institutional laboratories on venous blood collected in overnight fasting conditions and prior to any therapeutic procedure. Stage was coded according to the FIGO staging system based on the results of the diagnostic workup, while tumour grade was locally assessed by an expert pathologist. Participants' characteristics were descriptively analyzed for the overall study population and in a subgroup of 70 patients for whom data on body mass index (BMI) were available. FIGO stage and grade were compared by categories of pre-treatment fasting glucose defined upon the median value, i.e., 89 mg/dl. The association of interest was tested in regression models including BMI. Results: For the overall study population, patients in the lowest category of fasting glucose were significantly more likely to exhibit a FIGO stage III-IV at diagnosis compared with their counterpart in the highest glucose category (81.3 vs 66.7%, p: 0.021). Subgroup analysis in 70 patients with BMI data confirmed this association (81.5 vs 55.8, p: 0.049), which remained significant when tested in regression models including BMI (OR: 0.28 95% CI 0.086-0.89, p: 0.031). No relevant evidence emerged when testing the association between fasting glucose and tumour grade. Conclusions: In patients diagnosed with epithelial ovarian cancer, pre-treatment glucose levels appear to be inversely associated with FIGO stage. Further studies are warranted to eventually confirm and correctly interpret the implications of this novel finding.
AB - Background: Over the last twenty years, the efforts of the scientific community devoted to the comprehension and treatment of ovarian cancer have remained poorly remunerative, with the case-fatality ratio of this disease remaining disappointedly high. Limited knowledge of the basic principles regulating ovarian carcinogenesis and factors impacting the course of disease may significantly impair our ability to intervene in early stages and lessen our expectations in terms of treatment outcomes. In the present study, we sought to assess whether metabolic factors and anthropometric indicators, i.e., pre-treatment fasting glucose and body mass index, are associated with renown cancer related prognostic factors such as tumour stage and grade at diagnosis. Materials and Methods: Study participants were 147 women diagnosed with epithelial ovarian cancer and treated with platinum based regimens and/or surgery at the Regina Elena National Cancer Institute of Rome, Italy. Glucose levels were assessed at the institutional laboratories on venous blood collected in overnight fasting conditions and prior to any therapeutic procedure. Stage was coded according to the FIGO staging system based on the results of the diagnostic workup, while tumour grade was locally assessed by an expert pathologist. Participants' characteristics were descriptively analyzed for the overall study population and in a subgroup of 70 patients for whom data on body mass index (BMI) were available. FIGO stage and grade were compared by categories of pre-treatment fasting glucose defined upon the median value, i.e., 89 mg/dl. The association of interest was tested in regression models including BMI. Results: For the overall study population, patients in the lowest category of fasting glucose were significantly more likely to exhibit a FIGO stage III-IV at diagnosis compared with their counterpart in the highest glucose category (81.3 vs 66.7%, p: 0.021). Subgroup analysis in 70 patients with BMI data confirmed this association (81.5 vs 55.8, p: 0.049), which remained significant when tested in regression models including BMI (OR: 0.28 95% CI 0.086-0.89, p: 0.031). No relevant evidence emerged when testing the association between fasting glucose and tumour grade. Conclusions: In patients diagnosed with epithelial ovarian cancer, pre-treatment glucose levels appear to be inversely associated with FIGO stage. Further studies are warranted to eventually confirm and correctly interpret the implications of this novel finding.
KW - Body mass index
KW - Epithelial ovarian cancer
KW - Fasting glucose
KW - FIGO stage
KW - Tumour grade
UR - http://www.scopus.com/inward/record.url?scp=84971571560&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84971571560&partnerID=8YFLogxK
U2 - 10.7150/jca.13578
DO - 10.7150/jca.13578
M3 - Article
VL - 7
SP - 516
EP - 522
JO - Journal of Cancer
JF - Journal of Cancer
SN - 1837-9664
IS - 5
ER -